PEX14 and Alzheimer disease: In a transgenic AD mouse model, the peroxisome density (as measured by the level of PEX14) decreased, whereas the levels of ABCD3, catalase and acyl-CoA oxidase 1 increased during the first 3 months with a return to control level at 6 to 18 months of age [24].